🔗 Share this article Individuals Stopping Anti-Obesity Jabs Put On Pounds Four Times Faster Than People Using Diet and Exercise Weight management involves long-term strategies. Fresh analysis indicates that people who stop using new weight-loss injections like Wegovy and Mounjaro may regain reduced body mass far faster than those who end conventional diet and exercise programs. Research printed in a leading health publication demonstrates that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping. "People purchasing such treatments must be aware of the risk of rapid weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb. Such speed of recovery suggests a return to starting mass within about one and a half years. Analyzing Treatments The study, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods. Scientists note that individuals who lose weight through dieting generally have a slower creep back—approximately 0.1 kg a month—once they finish. Explaining the Quick Regain Experts suggest the way of the jabs explains the accelerated rebound. These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger. "Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk." A Lifelong Condition? Health authorities advise the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications. Many experts argue that, given the significant potential of weight regain, the treatment is often ongoing. This perspective is echoed by pharmaceutical companies, who say that the results "emphasize the persistent character of obesity," akin to managing diseases like high blood pressure. Patient Testimonies Individuals who have come off the medication report a intense return of appetite. "It was like a trigger activating and I was suddenly ravenous," described one woman. This difficulty is exacerbated if patients have not adopted lasting dietary or behavioural modifications during treatment. Widespread Use Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial. Use is greater among women than men. The 40s and 50s demographic shows the highest level of interest. Many access the drugs through private healthcare rather than public health services. In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and long-term success likely depends on integrated lifestyle support.
Weight management involves long-term strategies. Fresh analysis indicates that people who stop using new weight-loss injections like Wegovy and Mounjaro may regain reduced body mass far faster than those who end conventional diet and exercise programs. Research printed in a leading health publication demonstrates that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping. "People purchasing such treatments must be aware of the risk of rapid weight regain when the treatment ends," stated lead investigator Dr. Susan Jebb. Such speed of recovery suggests a return to starting mass within about one and a half years. Analyzing Treatments The study, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods. Scientists note that individuals who lose weight through dieting generally have a slower creep back—approximately 0.1 kg a month—once they finish. Explaining the Quick Regain Experts suggest the way of the jabs explains the accelerated rebound. These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger. "Artificially providing the hormone concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Stopping of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk." A Lifelong Condition? Health authorities advise the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications. Many experts argue that, given the significant potential of weight regain, the treatment is often ongoing. This perspective is echoed by pharmaceutical companies, who say that the results "emphasize the persistent character of obesity," akin to managing diseases like high blood pressure. Patient Testimonies Individuals who have come off the medication report a intense return of appetite. "It was like a trigger activating and I was suddenly ravenous," described one woman. This difficulty is exacerbated if patients have not adopted lasting dietary or behavioural modifications during treatment. Widespread Use Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial. Use is greater among women than men. The 40s and 50s demographic shows the highest level of interest. Many access the drugs through private healthcare rather than public health services. In conclusion, researchers caution that while GLP-1 drugs are powerful agents for weight loss, they are not a standalone solution and long-term success likely depends on integrated lifestyle support.